Lakefront Biotherapeutics

Forecast & Rating6 analysts currently cover Lakefront Biotherapeutics, with about 33.3% giving a positive rating — meaning they expect the stock to rise. The average price target is $30.85, about 5.0% upside from the current price of $29.37. Price targets range from $21.75 to $45.03 — a wide spread, showing clear disagreement over just how much Lakefront Biotherapeutics can rise. For you, this means most institutions are cautious on Lakefront Biotherapeutics's outlook. Data as of Sep 24, 2026; for reference only and not investment advice.